NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive childhood brain cancers. The program is supported by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research aims to address the challenge of achieving and maintaining therapeutic drug concentrations within brain tumors. While convection-enhanced delivery (CED) can bypass the blood-brain barrier, therapeutic benefit is often limited by rapid drug clearance. The Mayo Clinic team will evaluate a combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, potentially prolonging therapeutic exposure. The project begins with large animal studies and may expand to human studies if successful.
The study will utilize NeuroOne's investigational drug delivery neural device, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach enables targeted therapy with real-time physiologic monitoring, offering insights into drug delivery and effects on the surrounding neural environment.
David Wambeke, Chief Business Officer of NeuroOne, stated: "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording."
NeuroOne's drug delivery platform is part of a growing portfolio of initiatives, reflecting increasing interest from academic investigators and biopharmaceutical companies. The CCRF award marks a milestone in advancing this therapeutic approach toward clinical evaluation.
NeuroOne is a medical technology company focused on improving surgical care for neurological disorders. The company markets minimally invasive electrode technology with FDA-cleared product families including Evo® Cortical Electrodes and the OneRF® Ablation System. For more information, visit nmtc1.com.
